Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer

doi:10.13438/j.cnki.jdzk.2020.02.016

Abstract

Abstract:

The clinical efficacy and adverse effects of nab-paclitaxel in patients with relapsed extensive-stage small-cell lung cancer have been researched. Clinical data of 24 relapsed extensive-stage small-cell lung cancer patients who received nab-paclitaxel as single agent between June 2017 and June 2019 were collected, and the curative and adverse effects of the compound were evaluated. All patients were treated with 130 mg/m nab-paclitaxel on days 1, 8, and 15. The cycle was repeated every 4 weeks. Clinical efficacy was evaluated every two cycles. Results showed that among 24 patients, including 18 males and 6 females, the median age being 65 years （range 45～77 years）, 8 patients (33.3%) achieved partial response, 7 patients (29.2%) had a stable disease, and 9 patients (37.5%) had progressive disease. The objective response rate was 33.3%, and the disease control rate was 62.5%. The median progression-free survival was 3.6 months and median overall survival was 8.3 months. The major adverse reactions included neutropenia (37.5% ), alopecia (29.2% ), and sensory neuropathy (16.7% ). It can be concluded that nab-paclitaxel has curative effects, and its adverse effects are tolerable. Further research with a larger sample size is warranted to confirm these results.

Key words: nab-paclitaxel, extensive-stage small-cell lung cancer, chemotherapy

XU Chaojiu, ZHAO Jingsheng, CHEN Chaoying, LONG Jian, LIANG Jing. Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer[J]. Journal of Jishou University（Natural Sciences Edition), DOI: 10.13438/j.cnki.jdzk.2020.02.016.

References

[1] VISHNU P, ROY V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer[J]. Breast Cancer (Auckl), 2011(5): 53-65.
[2] GRADISHAR W J, TJULANDIN S, DAVIDSON N, et al. Phase Ⅲ Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer[J]. J Clin Oncol, 2005, 23(31): 7794-7803.
[3] MARIA A B, CLORINDA S, ANTONIO R. Treatment of Advanced Non-Small Cell Lung Cancer[J]. J Thorac Dis, 2011, 3(2): 122-133.
[4] EISENHAUER E A, THERASSE P, BOGAERTS, et al. New Response Evaluation Criteria in Solid Tumours: Revised Recist Guideline (Version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
[5] 何敬波,雷琳,袁佳,等.二线不同化疗方案治疗小细胞肺癌的疗效和安全性比较[J].实用癌症杂志,2017,32(1):61-63.
[6] STEFFENS C C, ELENDER C, HUTZSCHENREUTER U, et al. Treatment and Outcome of 432 Patients with Extensive-Stage Small Cell Lung Cancer in First, Second and Third Line-Results from the Prospective German TLK Cohort Study[J]. Lung Cancer, 2019, 130: 216-225.
[7] VON PAWEL J, JOTTE R, SPIGEL D R, et al. Randomized Phase Ⅲ Trial of Amrubicin Versus Topotecanas Second-Line Treatment for Patients with Small-Cell Lung Cancer[J]. J Clin Oncol, 2014, 32: 4012-4019.
[8] JOTTE R, CONKLING P, REYNOLDS C, et al. Randomized Phase Ⅱ Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients with Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy[J]. J Clin Oncol, 2011, 29: 287-293.
[9] 徐朝久,张灿珍，丁纯志,等.拓扑替康联合顺铂治疗小细胞肺癌的临床研究[J].肿瘤防治研究,2004,31(12):776-778.
[10] MARIA A B, CLORINDA S, ANTONIO R. Treatment of Advanced Non-Small Cell Lung Cancer[J]. J Thorac Dis, 2011, 3(2): 122-133.
[11] RIZVI N A, RIELY G J, AZZOLI C G, et al. Phase Ⅰ/Ⅱ Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel as Initial Chemotherapy in Patients with Stage Ⅳ Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2008, 26(4): 639-643.
[12] YOSHIDA H, KIM Y H, OZASA H, et al. Albumin-Bound Paclitaxel for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer[J]. Mol Clin Oncol, 2016, 5(1): 213-215.
[13] NAITO Y, TAMIYA A, TAMIYA M, et al. Efficacy of Nanoparticle Albumin-Bound Paclitaxel Regimens for Relapsed Small-Cell Lung Cancer: A Retrospective Analysis[J]. Medicine, 2017, 96(35): e7884.
[14] MU J W, GAO S G, XUE Q, et al. A Matched Comparison Study of Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early-stage Nonsmall Cell Lung Cancer[J]. Chinese Medical Journal, 2015, 128(20): 2731-2735.